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Some phytochemicals with the characteristics of cytotoxicity and/or antimetastasis have generated intense interest among the
anticancerstudies.Inthisstudy,anaturalflavonoidbaicaleinwasevaluatedinbladdercancerin vitro and in vivo.Baicaleininhibits
5637 cell proliferation. It arrests cells in G1 phase at 100𝜇M and in S phase below 75𝜇M .Th ep r o t e i ne x p r e s s i o no fc y c l i nB 1a n d
cyclinD1isreducedbybaicalein.Baicalein-inducedp-ERKplaysaminorroleincyclinB1reduction.Baicalein-inhibitedp65NF-𝜅B
resultsinreductionofcellgrowth.Baicalein-inducedpGSK(ser9)hasalittleeffectinincreasingcyclinB1/D1expressioninstead.The
translationinhibitorcycloheximideblocksbaicalein-reducedcyclinB1,suggestingthatthereductioniscausedbyproteinsynthesis
inhibition. On the other hand, neither cycloheximide nor proteasome inhibitor MG132 completely blocks baicalein-reduced cyclin
D1, suggesting that baicalein reduces cyclin D1 through protein synthesis inhibition and proteasomal degradation activation. In
addition,baicaleinalsoinhibitscellinvasionbyinhibitingMMP-2andMMP-9mRNAexpressionandactivity.Inmouseorthotopic
bladder tumor model, baicalein slightly reduces tumor size but with some hepatic toxicity. In summary, these results demonstrate
the anti-bladder-tumor properties of the natural compound baicalein which shows a slight anti-bladder-tumor effect in vivo.
1. Introduction
Bladder cancer is the seventh most common type of cancer
in worldwide man [1] and fourth in man of United States
[2]. More than 90% of bladder cancers are transitional cell
carcinoma (TCC), and approximately 80% of TCC belong to
noninvasive papillary carcinoma that is a low-grade intrau-
rothelial neoplasia with high recurrence. The other 20% of
TCCs initiated from carcinoma in situ are at a high risk of
processing to muscle invasive disease with a substantial risk
for the development of distant metastasis [3, 4]. More than
10% of the low-grade papillary tumors eventually progress
to high-grade muscle invasive bladder tumors. Most of the
deaths from bladder cancer patients are due to invasive
cancer metastasis [5], which has been a leading problem
in the cancer therapy field. Multiple drugs chemotherapy
has been applied for the therapy of metastatic bladder
cancer; however, the adverse effect and resistance usually
limit its clinical result. Therefore, some phytochemicals with
the characteristics of cytotoxicity and/or antimetastasis have
generated intense interest among the anticancer studies.
Baicalein,oneoffourmajorflavonoidsexistedintheroot
of Scutellaria baicalensis Georgi, has excellent antioxidant
andanti-inflammatoryactivities[6,7].IntraditionalChinese
herb medicine, the root of Scutellaria baicalensis Georgi was
u s u a l l yg a t h e r e db e f o r eT o m b - S w e e p i n gD a ya n dd e c o c t e d
for the purpose of “cleansing heart” and “removing toxins,”
for example, cough with yellow sputum, jaundice, swelling
and pain of eye, and so on. Wogonin, another one of the
major flavonoids in the root of Scutellaria baicalensis Georgi,
h a sb e e nr e p o r t e dt or e d u c ei n fl a m m a t o r yc y c l o o x y g e n a s e -
2 expression by c-Jun inhibition [8]. In addition to the anti-
inflammatory effect of wogonin, baicalein has been reported
to apply in cancer therapy by its cytotoxicity [9–11]a n di t s2 Evidence-Based Complementary and Alternative Medicine
anti-metastasis activity [12–14]r ecen tl y .I nh uma npa ncr ea tic
cancer cells, 15∼50𝜇M baicalein induces apoptotic cell death
through downregulation of an antiapoptotic protein Mcl-
1[ 11]. In human bladder cancer cells, 60∼80𝜇Mb a i c a l e i n
retards cell growth by inhibiting CDC2 kinase activity
[9]. Sixty 𝜇M baicalein also induces bladder cancer cells
death, but baicalein-induced p-Akt and 𝗾-H2AX expression
plays a protective role against cell death [10]. Moreover,
10∼50𝜇M baicalein inhibits cell migration and invasion
through inhibiting MMP-2/9 activity in human hepatoma
cells [12]a n dh u m a nb r e a s tc a n c e rc e l l s[ 13]. In human skin
carcinoma, 40𝜇M baicalein inhibits cell invasion through
inhibiting an anchor protein Ezrin expression [14]. Recently,
baicalein is proven to be genotoxic without producing chro-
mosomal alterations and mutagenesis which results in the
severe side effect in cancer chemotherapy [15]. According to
theabovedata,baicaleinisacandidateworthdevelopmentin
anticancer therapy.
In this study, the anticancer effect of baicalein was
analyzed in bladder cancer cells in vitro a n di na no r t h o t o p i c
bladder tumor model in vivo. In vitro,t h ec o r r e l a t i o no f
baicalein-induced change in Akt, ERK, p38, and p65NF-𝜅B
pathways and cell viability was analyzed. In vivo,t h ea n t i t u -
mor effect and renal and hepatic toxicities were evaluated.
2. Materials and Methods
2.1. Cell Culture and Drug Preparation. Human bladder
papillarytransitionalcell carcinoma5637 cells were obtained
from the Bioresource Collection and Research Center
(Hsinchu, Taiwan). Mouse bladder carcinoma MB49 cells
were kindly provided by Dr. Timonthy L. Ratliff (Purdue
CancerCenter,WestLafayette,IN,USA).5637andMB49cells
were maintained in RPMI 1640 medium supplied with 10%
fetalbovineserum(FBS),1%penicillin,and1%streptomycin.
Cells were incubated in a CO2 incubator at 37
∘C, with
5% CO2 a n d9 5 %fi l t e r e da i r .B a i c a l e i nw a si s o l a t e df r o m
the root of Scutellaria baicalensis Georgi, identified [16]
and dissolved in DMSO. For culture cell assay, baicalein
was added in culture medium containing 0.1% DMSO.
For mouse assay, baicalein was intraperitoneally injected
in mice containing 10% DMSO and 90% propylene glycol
(0.8mg/100𝜇L/mouse).
2.2. Reagents and Antibodies. 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), propidium iodide
(PI), ribonuclease A (RNase A), propylene glycol, MG-132,
and crystal violet were purchased from Sigma (St. Louis,
MO, USA). Anti-phospho-AKT(thr308), anti-phospho-
AKT(ser473), and anti-cyclin D1 antibodies were purchased
from Santa Cruz (Santa Cruz, CA, USA). Anti-𝗼-tubulin,
anti-𝗽-actin, and anti-phospho-GSK-3𝗽(ser9) antibodies
were purchased from GeneTex (Taichung, Taiwan). Anti-
cyclin B1 was purchased from Epitomics (Burlingame, CA,
USA). Anti-Bub3 was purchased from BD Biosciences
(San Jose, CA, USA). Anti-p65NF-𝜅B, anti-phospho-
ERK(thr202/tyr204), and anti-phospho-p38(thr180/tyr182)
were purchased from Cell Signaling Technology (Danvers,
MA, USA). The Millicell Hanging Cell Culture Inserts of
Transwell system was purchased from Millipore (Billerica,
MA, USA). Peroxidase-conjugated secondary antibodies
were purchased from Jackson ImmunoResearch (West
Grove, PA, USA).
2.3. Cell Viability Assay. Cell number was determined by
colorimetric MTT assay. 5637 cells were cultured in 24-
well plates at a density of 5×10
4 cells/well. After 24h, cells
were incubated with various concentrations of baicalein or
0.1% DMSO for another 24∼72h. Then MTT was added into
medium for 2h, the medium was discarded, and DMSO
w a sa d d e dt od i s s o l v et h ef o r m a z a np r o d u c t .E a c hw e l lw a s
measured by light absorbance at 490nm. The result was
expressed as a percentage, relative to 0.1% DMSO-treated
control group.
2.4. Cell Cycle Analysis. Around 2×10
6 5637 cells were
seeded in 100mm dishes. After 24h incubation for attach-
ment, baicalein or DMSO was added. After baicalein treat-
ment for 24h and 48h, cells were trypsinised, centrifuged,
a n dfi x e dw i t hi c e - c o l d7 5 %e t h a n o lo v e r n i g h ta t4
∘C. After
removingtheethanol,cellswerestainedwithaDNAstaining
solution (containing 1mg/mL PI and 10mg/mL RNase A
d i s s o l v e di nP B S )f o r3 0m i na tr o o mt e m p e r a t u r e .Th eD N A
content of the stained cells was measured using a FACScan
flow cytometer. The cell doublets were removed by gating the
left area of FL2-W/FL2-A plot for analysis. Cell cycle data
fromflowcytometrywasanalysedusingModFitLTsoftware.
2.5. Cell Migration Assay. 5637 cells were seeded in 6-well
plates. After cells had reached confluence, a wound was
made by a 200𝜇L plastic tip in each well. The wells were
then washed twice with PBS to remove cell debris and
then incubated with culture medium with DMSO (control)
or baicalein. After 24h incubation, each well was pho-
tographed by a phase contrast microscopy. The empty area
was calculated by computer, and the cell mobility was calcu-
lated by (scratch area − empty area of baicalein treatment)
×100%/(scratcharea−emptyareaofcontrol).Measurements
wereperformedintriplicateandpresentedasmean±SEfrom
three independent experiments.
2.6. Cell Invasion Assay. The invasion assay was analyzed
using a Matrigel (BD Biosciences)-coated Transwell system
(Millipore). The upper chamber of the transwell was coated
with 25𝜇gM a t r i g e l .5 6 3 7c e l l s( 1×10
5) in serum-free RPMI-
1640mediawereseededontoMatrigel-coatedTranswell.The
upper and lower chamber media were added baicalein or
0.1% DMSO. In the lower chambers, 10% FBS was added as
achemoattractant.Aftera24hincubationtime,thecellsthat
remained on the upper surface of the filter membrane were
removed, and the cells on the opposite surface of the filter
membrane were stained with 4% paraformaldehyde for 30s
and photographed under microscopy at 200x magnification.
The number of migrated cells was counted in five randomly
chosen microscope fields.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Effect of baicalein on cell growth. (a) Cytotoxicity of baicalein in 5637 bladder cancer cells. 5637 cells were initially seeded at 1×10
5
cellsperwellin24-wellplatesandthentreatedwithvariousconcentrationsofbaicaleinorvehicle(0.1%DMSO)for24h.Thecellviabilitywas
measured by MTT assay. Measurement is performed from three independent experiments (
∗𝑃 < 0.05 compared with vehicle). (b) Baicalein
dose-dependentlyinhibitscellgrowthof5637cells.Cellswereinitiallyseededat1×10
5 cells(da y-1)perwellin2 4-wellpla tesandthentr ea ted
with various concentrations of baicalein or vehicle (0.1% DMSO) for 24∼72h. The cell number was counted by trypan blue dye exclusion
assay. The dotted line indicates the cell number on day 0.
2.7. RT-PCR. Total RNA was isolated from cells. Reverse
transcription (RT) was performed on 2𝜇go ft o t a lR N Ab y
1.5𝜇M random hexamer and RevertAid reverse transcriptase
(Fermentas); then 1/20 volume of reaction mixture was
used for PCR with MMP-2 specific primers (5
򸀠CTT-
CCAAGTCTGGAGCGATGT3
򸀠,5
򸀠TACCGTCAAAGG-
GGTATCCAT3
򸀠), MMP-9 specific primers (5
򸀠AAGATG-
CTGCTGTTCAGCGGG3
򸀠,5
򸀠GTCCTCTGGGCACTG-
CAGGAT3
򸀠), and GAPDH specific primers (5
򸀠CGG-
ATTTGGTCGTATTGG3
򸀠,5
򸀠AGATGGTGATGGGAT-
TTC3
򸀠). The PCR products were analyzed by 1% agarose gel.
2.8. Gelatin-Zymography Assay. The enzymatic activities
of MMP-2 and MMP-9 were determined by gelatin-
zymography. 3×10
6 cells were seeded in 10cm dish for 24h
and then maintained in serum-free medium with various
concentrations of baicalein. The conditioned medium was
collected 24h after drug treatment, concentrated by using an
Amicon Ultracel YM-10 filter. Twenty micrograms of protein
obtained from the concentrated medium was mixed with
nonreducing sample buffer and subjected to electrophoresis
( 8 %S D S - P A G Ec o po l y m e ri z ew i th0 . 1 %g e l a ti na ss u b s tr a t e ) .
The gel was washed twice (15min/time) with 2.5% Triton X-
100andincubatedat37
∘Cfor16∼20hin50mMT ris-HCl(pH
7.8), 10mM CaCl2,a n d0 . 0 1 %N a N 3.Thegelwasstainedwith
0.15% Coomassie brilliant blue R-250 and destained in 50%
methanol and 10% acetic acid until the gelatinolytic activities
were detected as clear bands against a blue background.
2.9. Mouse Orthotopic Bladder Tumor Model. The female
C57BL/6 mice aged five to six weeks were provided by the
National Laboratory Animal Center (Taipei, Taiwan) and
maintained at our animal care facility for one week prior to
use. The implantation of murine bladder cancer cells MB49
into C57BL/6 mice was carried out similarly as previous
report [17, 18]. After MB49 inoculation (day 1), mice were
randomly assigned to two groups (10 mice/group). One
group was intraperitoneally treated with vehicle (10% DMSO
and 90% propylene glycol), and the other group received
0.8mg/mouse baicalein intraperitoneally for 9 times. At the
21th day, the mice were sacrificed and the bladder volumes
were measured before formalin fixation. After cutting into
4𝜇msections,theslidesofeachmousewereconfirmedunder
amicr osco peinhistologyb yhema to xylinandeosinstaining.
The experiment was approved by the Institutional Animal
Care and Use Committee of National Chiayi University.
2.10. Statistical Analysis. The values shown are mean ±
SEM. Data are statistically evaluated by one-way ANOVA of
SigmaPlot11.0andshownsignificantlydifferentin
∗𝑃 < 0.05,
∗∗𝑃 < 0.01,a n d
∗∗∗𝑃 < 0.001.
3. Results
3.1. Cytotoxicity and Proliferation Inhibition of Baicalein in
5637 Bladder Cancer Cells. Cytotoxicity of baicalein was
analyzed by MTT assay. The result shows that baicalein
dose-dependently inhibits cell viability after 24h treatment
(Figure 1(a)). Below 50𝜇M, baicalein did not induce cell
death because there were no floating cells after treatment.
When the concentration reached 100𝜇M, baicalein causes
3 3 %c e l ln u m b e rd o w nw i t hd e a dfl o a t i n gc e l l si nt h ec u l t u r e4 Evidence-Based Complementary and Alternative Medicine
medium.Todistinguishthefactofcelldeathandproliferation
inhibition, the direct cell count analysis was applied after
b a i c a l e i nt r e a t m e n t .Th er e s u l to fFigure 1(b) suggests that
under 50𝜇M, baicalein does not reduce total cell number
after treatment for 72h. Only for the concentration higher
than 75𝜇M, baicalein induces cell death dose-dependently.
These data suggest that baicalein induces growth inhibition
at a dose lower than 50𝜇M and causes cell death at a dose
higher than 75𝜇Mi n5 6 3 7c e l l s .
3.2. Baicalein Induces Cell Cycle Arrest and Decreases Cyclin
B1/D1 Expression of 5637 Bladder Cancer Cells. The cell cycle
distribution changed by baicalein was analyzed by flow cyto-
metric assay. Baicalein arrests cells in S phase after 24h treat-
ment at the concentration under 75𝜇Ma n di nG 1p h a s ea t
100𝜇M.Aftertreatmentfor48h,100𝜇Mbaicaleincontinued
to arrest cells in G1 without sub-G1 formation (Figure 2(a)).
It suggests that baicalein, less than 50𝜇M, caused S phase
arrest without significant cytotoxicity. One hundred 𝜇M
baicalein arrested cells in G1 phase and induced cytotoxicity.
One of G1/S transition promotion factors, cyclin D1, was
dose-dependently decreased by baicalein (Figure 2(b)). It
may contribute the reason to 100𝜇M baicalein-induced G1
arrest. Baicalein also decreased cyclin B1 expression dose-
dependently (Figure 2(b)). Because cyclin B1 is an essential
factorforenteringG2/Mphase,baicalein-decreasedcyclinB1
m a yl e a dt oSp h a s ea r r e s t .B a i c a l e i ni m m e d i a t e l yd e c r e a s e s
cyclin D1 expression after treatment for 2h (Figure 2(b)). It
suggeststhat100𝜇Mbaicaleineffectivelyandquicklyinhibits
cell cycle progression at G1 phase.
3.3. Effect of Baicalein on the Regulation of Upstream Signal
Factors. The intracellular signal factors p-GSK3𝗽(ser9),
p-AKT(thr308), p-AKT(ser473), p-ERK, and p-p38 were
analyzed after baicalein treatment. The result of Figure 3(a)
indicates that baicalein increases the phosphorylation of
GSK3𝗽(ser9), ERK(thr202/tyr204), and p38(thr180/tyr182).
Though baicalein decreased the phosphorylation of
AKT(thr308) and did not change p-AKT(ser473), the
downstream GSK3𝗽(ser9) was still phosphorylated at 24h
treatment. The time course of these baicalein-induced
changes was also analyzed. As shown in Figure 3(b),
baicalein inhibited p-AKT(thr308) phosphorylation from
2h to 24h; it suggests that baicalein inhibits Akt activity.
GSK3𝗽(ser9) was phosphorylated by baicalein from 2h to
24h, suggesting that baicalein also inhibits GSK3𝗽 activity.
Both ERK and p38 pathways were early activated from
2h to 24h after baicalein treatment, ERK especially. The
effect of baicalein on p65NF-𝜅B was also analyzed. Without
extracellular stimulation, most of p65NF-𝜅Bw a sf o u n di n
cytoplasmic fraction in 5637 cells (Figure 3(c)). Baicalein
dose-dependently inhibited the nuclear protein expression
of p65NF-𝜅B( Figure 3(c)). In summary, baicalein inhibits
AKT and GSK3𝗽 activities, activates ERK and p38 pathways,
and inhibits p65NF-𝜅B-driven signals.
3.4.EffectofV ariousSignalProteinI nhibitorsontheBaicalein-
Changed Cyclin B1/D1 Expression and Cell Viability. In order
to understand the correlation between upstream signals and
cyclin B1/D1 reduction, some specific inhibitors were used.
Lithium chloride (LiCl) induces GSK3𝗽(ser9) phosphoryla-
tion and inhibits GSK3𝗽 activity [19, 20]. Baicalein or LiCl
increasedp-GSK3𝗽(ser9),butonlybaicaleindecreasedcyclin
B1/D1 expression (Figure 4(a)). It suggests that baicalein-
inhibited cyclin B1/D1 expression is not mediated by
GSK3𝗽 inhibition. On the contrary, LiCl dose-dependently
increased cyclin B1/D1 expression, it suggests that baicalein-
inhibited GSK3𝗽 pathway causes cyclin B1/D1 increase
instead. LY294002,theinhibitorofPI3K-Akt pathway,inhib-
ited the phosphorylation of AKT(ser473) but increased the
phosphorylation of GSK3𝗽(ser9) (Figure 4(b)). However,
unlike baicalein, LY294002 did not reduce cyclin B1/D1
expression (Figure 4(b)). U0126, the inhibitors of MEK-
ERK, slightly reversed baicalein-decreased cyclin B1 but not
cyclin D1 (Figure 4(c)). The p38 kinase inhibitor SB203580
did not reverse baicalein-decreased cyclin B1/D1 expression
(Figure 4(d)). Ro106-9920, an inhibitor of p65NF-𝜅B, did
not decrease cyclin B1/D1 expression (Figure 4(e)). These
data indicate that baicalein-inhibited cyclin B1 is slightly
mediated by ERK activation. The relationship of cell viability
and baicalein-induced change in p-GSK3𝗽(ser9), p-ERK, p-
p38, and p65NF-𝜅B was also analyzed. Using MTT assay
(Figure 4(f)), MEK-ERK inhibitor U0126 and p38 kinase
inhibitor SB203580 did not affect baicalein-reduced cell
viability;thePI3KinhibitorLY294002deterioratedbaicalein-
reduced cell viability; the p65NF-𝜅Bi n h i b i t o rR o 1 0 6 - 9 9 2 0
reduced cell viability directly. It suggests that baicalein-
induced p38, ERK, and GSK3𝗽(ser9) phosphorylation does
not play essential roles in cell growth inhibition. Only the
baicalein-inhibited p65NF-𝜅B activity leads to reduction of
cell viability. In order to find out baicalein-reduced cyclin
B1/D1 caused by de novo protein synthesis inhibition or pro-
teasomal degradation stimulation, the translation inhibitor
cycloheximide and the proteasome inhibitor MG132 were
used for this study. After cyclohexamide treatment, baicalein
didnotreducecyclinB1anymore(Figure 4(g)).Butbaicalein
still reduced cyclin D1 expression in the presence of cyclo-
heximide or MG132 (Figure 4(g)). It suggests both de novo
protein synthesis inhibition and proteasomal degradation
stimulation are involved in baicalein-reduced cyclin D1
expression, and cyclin B1 decrease is only caused by de novo
protein synthesis inhibition.
3.5. Baicalein Blocks Migration and Invasion of 5637
Bladder Cancer Cells. Using scratch assay, baicalein dose-
dependently inhibited cell migration (Figure 5(a)). At
100𝜇M, baicalein shows 60% inhibition in cell migration,
which is more effective than the inhibition in cell viability
(33% inhibition at 100𝜇M, Figure 1(a)). By matrigel-coated
invasion assay, baicalein also shows a significant inhibition
dose-dependently (Figure 5(b)). On the other hand,
baicalein reduced MMP2 and MMP9 mRNA expression
(Figure 5(c))a n de n z y m a t i ca c t i v i t y( Figure 5(d))i n5 6 3 7
cells. It suggests that the baicalein-inhibited MMP2/9
activity may contribute its anti-migration and anti-invasion
activity.Evidence-Based Complementary and Alternative Medicine 5
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Figure2:Effectofbaicalein oncellcycle phasedistributionin5637cells.(a)Baicaleininducescellcyclearrest.Cellsweretreatedwithvehicle
or baicalein for 24 and 48h, then were collected for cell cycle analysis (
∗𝑃 < 0.05,
∗∗𝑃 < 0.01,
∗∗∗𝑃 < 0.001comparedwithvehicle).(b)Effect
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Figure 3: Influence of baicalein on the signal pathways. (a) Effect of baicalein on the phosphorylation of GSK3𝗽,A K T ,E R K ,a n dp 3 8 .5 6 3 7
c e l l sw e r et r e a t e dw i t h0 . 1 %D M S Oo rb a i c a l e i nf o r2 4h .( b )T i m e - c o u r s e of baicalein-changed signal protein phosphorylation. 5637 cells
treated with 100𝜇M baicalein or 0.1% DMSO for 2, 6, 12, and 24h. The total cell lysates were extracted for western blot analysis. 𝗽-Actin was
usedasaloadingcontrol.(c)Effectofbaicaleinonthenuclearp65NF-𝜅Bexpression.5637cellsweretreatedwith0.1%DMSOorbaicaleinfor
24h.ThecytoplasmicandnuclearextractswerepreparedforWesternblotanalysis.𝗼-TubulinandBub3aretheloadingcontrolofcytoplasmic
and nuclear fraction, respectively.
3.6. Baicalein Slightly Inhibits Tumor Growth with Some
Hepatotoxicity in a Mouse Orthotopic Bladder Tumor Model
In Vivo . Ba sedo nth ea n tigr o w tha n da n tim e ta s ta s i sacti vi ty
o fb a i c a l e i ni nc e l la s s a y ,t h ein vivo antitumor assay was
analyzed. After bladder cell implantation on day 1, baicalein
treatmentstartedonday8.Thetreatmentdidnotshowtoxic-
ityinappearanceandbodyweight(Figure 6(a)).Baicaleindid
not significantly reduce bladder size, but the mean bladder
volume was still reduced in baicalein-treated mice (from
49.5mm
3 to35.9mm
3 inFigure 6(b)).Thebloodbiochemical
analysisshowsnosignificantchangeinserumBUNandcrea-
tininebetweencontrolandbaicaleintreatmentgroups,alittle
increaseinGPTvaluebutwithoutstatisticalsignificance,and
asignificantincreaseinserumGOT(Table 1).Itsuggeststhat
baicalein treatment causes some hepatic toxicity in mice.
4. Discussion
This study provides some new information about baicalein
used in the anticancer therapy. In cell study, baicalein
decreases cyclin B1 protein expression through inhibiting de
novo protein synthesis and inhibits cyclin D1 by inhibiting
protein synthesis and promoting proteasomal degradation.
Table 1: Effect of vehicle and baicalein on the plasma biochemical
parameters of mice at termination of treatment. Values are mean ±
SE.
Vehicle Baicalein
Blood urea nitrogen (BUN)
(mg/dL)
22.8 ± 2.7 22.7 ± 1.8
Creatinine (mg/dL) 0.39 ± 0.01 0.39 ± 0.01
Glutamate oxaloacetate
transaminase (GOT) (U/L)
66.0 ± 6.5 108.1 ± 16.6
∗
Glutamate pyruvate
transaminase (GPT) (U/L)
27.2 ± 1.7 44.4 ± 3.6
∗𝑃 < 0.05 compared with vehicle.
Baicalein-inhibited cyclin B1 is partially mediated by ERK
activation. Among the signal transduction molecules AKT,
GSK3𝗽,ERK,p38,andp65NF-𝜅B,p65NF-𝜅Binhibitionplays
the most important role in baicalein-reduced cell viability.
In mouse orthotopic bladder tumor model, baicalein has a
little inhibition effect on orthotopic bladder tumor growth
but with some hepatic toxicity.
Baicalein produces different cytotoxicity in different cell
lines. For example, it causes cell cycle arrest at G1 phaseEvidence-Based Complementary and Alternative Medicine 7
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Figure4:Effectofvariousinhibitorsonbaicalein-reducedcyclinB1/D1expression.(a–e)EffectofLiCl(a),LY294002(b),U0126(c),SB203580
(d), and Ro106-9920 (e) on baicalein-reduced cyclin B1/D1 expression. (f) Effect of various inhibitors on baicalein-inhibited cell viability. All
above inhibitors were pretreated for 1h and baicalein treatment for 24∼72h. The concentration of each chemicals: baicalein is 100𝜇Ma n d
others are 10𝜇M. (g) Effect of cycloheximide or MG132 on baicalein-reduced cyclin B1/D1 expression. Cycloheximide was pretreated for
30min and baicalein treatment for 1h in cyclin D1 detection and baicalein treatment for 6h in cyclin B1 detection. MG132 was pretreated for
1h and baicalein treatment for 6h. The extracted cell lysates or nuclear proteins were analyzed by western blot.
in breast cancer [21] and oral squamous cell carcinoma
[22], at S phase in lung nonsmall carcinoma cell [23]a n d
at G2/M phase in BFTC905 bladder cancer cells [9]. The
differences may be caused by different doses and different
cells used. In 5637 bladder cancer cells, baicalein arrests cells
at S phase under 75𝜇Ma n da tG 1p h a s ea t1 0 0𝜇Mw i t h o u t
apoptotic cells (Figure 2(a)). In pancreatic carcinoma PaCa
cells [11], bladder cancer BFTC905 cells [9], and colorectal
carcinoma HCT116 cells [10], baicalein induces cell apoptotic
death at the dose between 5 to 60𝜇M. Baicalein also has a
wide range on cytotoxicity of different cell lines, the IC50 is
under 20𝜇M in gastric cancer cells AGS and MKN-28 [24],8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Anti-migration and anti-invasion activities of baicalein in 5637 cells. (a) Baicalein inhibits 5637 cell migration. Bottom chart is
the percentage of migrated cells as control is 100%. (b) Baicalein inhibits 5637 cell invasion. Bottom chart is the percentage of invaded cells
as control is 100%. (c) Effect of baicalein on the mRNA expression of MMP-2 and MMP-9. Bottom charts are the quantitative results from
three independent experiments. (d) Effect of baicalein on the activities of MMP-2 and MMP-9. The conditioned medium was collected 24h
after drug treatment. Twenty micrograms of protein obtained from the concentrated medium was analyzed by gelatin-zymography assay.
(
∗𝑃 < 0.05,
∗∗𝑃 < 0.01,
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Figure 6: The antitumor effect of baicalein in vivo. (a) Mouse body weight and drug schedule in the mouse orthotopic bladder tumor model.
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Figure 7: The pathway scheme of baicalein on the cell proliferation inhibition and cell metastasis inhibition in human bladder cancer cell
5637. The anti-proliferation and anti-metastasis activities of baicalein may contribute the anti-bladder-tumor effect in vivo.
prostate carcinoma LNCaP [25], and JCA-1 [26], between 20
to 50𝜇Mi nl e u k e m i aH L - 6 0[ 27], bladder cancer BFTC905
[9],hepaticcancerHepG2[28],andmyelomacellU266[29],
a n dm o r et h a n1 0 0𝜇M in 5637 bladder cancer (Figure 1(a)),
oral squamous carcinoma HSC-3 [22], leukemia THP-1, and
osteogenic cancer cell HOS [30]. Although the detail mecha-
nisms about the wide-range cytotoxicity are still unclear, this
property may provide a specific and lower hazard anticancer
effect for the higher sensitive tumors.
PI3K, the upstream signal of AKT, has been reported
to be inhibited by baicalein [31]. In our study, baicalein
inhibits pAKT(thr308) phosphorylation and has no influ-
ence on pAKT(ser473) (Figure 2(b)). The pAKT inhibition
phenomenon also has been reported in prostate cancer
cell DU145 [32] and oral squamous carcinoma HSC-3 [22].
On the other hand, the pAKT(ser473) activation has been
reported in bladder cancer BFTC905 [9, 10]. Because the
pAKT(thr308) phosphorylation site is the direct target site
for PI3K-PDK1 [33], it will be downregulated after PI3K
inhibition by baicalein (Figure 4(b)). The ser473 site of
AKT is phosphorylated by rictor-mTOR [34], not PI3K;
therefore, it may be the reason for the no effect of baicalein10 Evidence-Based Complementary and Alternative Medicine
on the phosphorylation of pAKT(ser473). Even though the
pAKT(thr308) is decreased by baicalein, pGSK3𝗽(ser9), one
AKT downstream [35], is still phosphorylated by baicalein
(Figure 3(b)). Because the phosphorylation of pGSK3𝗽(ser9)
is achieved by numerous kinases, not only AKT [35],
baicalein-inducedpGSK3𝗽(ser9)m a ybeca u sedb yth einfl u-
ence of other kinase(s).
NF-𝜅B, an important inflammatory transcription factor,
is inhibited by baicalein in 5637 cells (Figure 3(c)). Baicalein-
inhibited p65NF-𝜅B activation has also been reported in
human mast cells [36], mouse macrophages [37, 38], human
myeloma cells [29], and brain microglia [39, 40]. According
to the important role of p65NF-𝜅Bi nt u m o rp r o g r e s s i o na n d
metastasis [41, 42], the inhibition of baicalein on nuclear
NF-𝜅B is a critical function in its anti-inflammation and
anticancer application. In human hepatoma cells, baicalein
shows anti-migration property with NF-𝜅Bi n h i b i t i o n[ 12].
There is one report indicates that GSK3𝗽 inhibition results
ininhibitingNF-𝜅Bactivity[43];therefore,themechanismof
baicalein-inhibitedp65NF-𝜅Bactivitymaybepartiallymedi-
atedbybaicalein-inhibitedGSK3𝗽.I nFigure 4(f),amongthe
4 signal inhibitors, the cell viability decreases at most by NF-
𝜅Bi n h i b i t o rR o 1 0 6 - 9 9 2 0 ,w h i c hi n d i c a t e st h a tN F - 𝜅Bi sa
critical factor for proliferation of 5637 cells.
Baicalein inhibits the protein expression of cyclin B1 [9,
23, 44]a n dc y c l i nD 1[ 22, 32, 44], has also been reported
by some studies, but the mechanism is still unclear. In
this study, we first suggest that baicalein decreases cyclin
B1 expression through inhibiting de novo protein synthesis
but not promoting proteasomal degradation and decreases
cyclin D1 by both ways (Figure 4(g)). On the other hand,
cyclin B1 reduction is partially mediated by ERK activation
(Figure 4(c)). Luteolin, a natural flavonoid with structure
similar to baicalein, decreases cyclin D1 expression by
increasing proteasomal degradation [45]. Though the struc-
tures are similar between baicalein and luteolin, the mecha-
nismsforcyclinD1reductionaredifferent.Luteolinenhances
proteasomal degradation via decreasing GSK3𝗽(ser9) phos-
phorylation, but baicalein increases GSK3𝗽(ser9) phospho-
rylation (Figures 3(a) and 3(b)). Therefore, there is (are)
other pathway(s) for inducing cyclin D1 degradation by
baicalein.
In addition to anti-proliferation, baicalein also inhibits
cancer cell metastasis. Either in scratch assay (Figure 5(a))
or in Matrigel-coated transwell assay (Figure 5(b)), they
point out the anti-migration and anti-invasion property of
baicalein. In this study, we confirm this inhibition, like
others [12, 13], mediated by inhibiting MMP-2/9 activities
(Figure 5(d)). The correlated signal pathways need to be
further investigated. In the orthotopic bladder tumor model,
baicalein shows a little effect on inhibiting bladder tumor
growth (Figure 6). One report indicates that baicalein sig-
nificantly reduces tumor volume in a nude mice model [12].
Comparingthesetwoanimalmodels,weusehigherdoseand
lower frequency of baicalein, which may result in the lower
efficiency. But it still notices that baicalein induces hepatic
toxicity with GOT value increase. In order to avoid hepatic
toxicity, it is better to use baicalein locally, for example, by
intravesical application for bladder tumor therapy.
5. Conclusions
Inthisstudy,baicaleindecreasescyclinD1proteinexpression
through inhibiting de novo protein synthesis and promoting
proteasomal degradation and decreases cyclin B1 by inhibit-
ing de novo protein synthesis. Baicalein-inhibited cyclin B1
expressionisslightlymediatedbyERKactivation.Themech-
anism of baicalein in anti-proliferation and anti-metastasis
is concluded in Figure 7. Among the signal transduction
molecules AKT, GSK3𝗽,E R K ,p 3 8 ,a n dp 6 5 N F - 𝜅B, p65NF-
𝜅B inhibition plays the most important role in baicalein-
reduced cell viability. In mouse orthotopic bladder tumor
model, baicalein has a little effect on orthotopic bladder
tumor growth inhibition but with some hepatic toxicity.
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